Shuhong Shi,Hui Zhang. Expression of Hpa and CD222 in bladder carcinoma and analysis of clinico-pathologic correlation. Oncol Transl Med, 2014, 13: 283-287.
Expression of Hpa and CD222 in bladder carcinoma and analysis of clinico-pathologic correlation
  
View Full Text  View/Add Comment  Download reader
KeyWord:bladder carcinoma; heparanase; CD222
Author NameAffiliation
Shuhong Shi Department of Blood and Oncology, Shaoyang Central Hospital, Shaoyang 422000, China 
Hui Zhang Department of Blood and Oncology, Shaoyang Central Hospital, Shaoyang 422001, China 
Hits: 6976
Download times: 7259
Abstract:
      Objective: Our study aimed to investigate the relationships between the clinico-pathologic features and the heparanase (Hpa) and CD222 expressions in bladder carcinoma. Methods: The expressions of Hpa and CD222 in 95 bladder carcinoma specimens and 20 paraneoplastic bladder tissues (controls) were assessed using the immunohistochemical staining method. Results: The positive expression rates of Hpa and CD222 in bladder carcinoma were 68.42% and 61.05%, respectively. The positive rate of Hpa was significantly higher in the carcinoma specimens than in the control specimens (P < 0.01). Similarly, the Hpa expression in the invasive bladder carcinoma was significantly higher than that in the non-invasive bladder carcinoma (P < 0.01). A positive correlation was observed between the expressions of Hpa and CD222 (P < 0.05). The expressions of Hpa and CD222 were significantly correlated with lymphatic invasion and TNM staging (P < 0.05). The 5-year survival rate was significantly higher in negative expression of the Hpa group than that in the positive expression group (P < 0.05). Compared with the non-co-positive expression group, the 5-year survival rate in the co-positive expression of Hpa and CD222 group was significantly lower (P < 0.05). Conclusion: High Hpa and CD222 expressions in tumor tissues were associated with the occurrence and development of bladder carcinoma. Our results provide helpful information for the further diagnosis and therapy of bladder carcinoma.
Close